Targeting SLC39A6: A Promising Approach To Drug Development (G25800)

Target Name: SLC39A6

NCBI ID: G25800

SLC39A6

Targeting SLC39A6: A Promising Approach To Drug Development

SLC39A6 (SLC39A6 variant 1) is a protein that is expressed in various tissues throughout the body. It is a member of the selective transmembrane protein (SMP) family and is involved in a variety of cellular processes, including intracellular signaling, neurotransmitter release, and tissue repair. SLC39A6 has also been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SLC39A6 is a potential drug target for a variety of therapies. One approach that is being explored is the use of small molecules to modulate SLC39A6 function and treat diseases associated with high levels of SLC39A6 expression. These small molecules can be administered to patients or used in drug combinations to target SLC39A6 and improve therapeutic outcomes.

One of the challenges in targeting SLC39A6 is its diverse expression patterns across different tissues and organisms. SLC39A6 is expressed in many different cell types, including neurons, muscle cells, and immune cells. This makes it difficult to predict how a small molecule will interact with SLC39A6 in different cell types and contexts. However, recent studies have identified a number of potential drug targets for SLC39A6 that can be targeted with small molecules.

One potential drug target for SLC39A6 is the SLC39A6-interactive protein (SIP), which is a protein that is expressed in many different cell types and is involved in intracellular signaling. SIP functions as a scaffold protein that can recruit other proteins to the plasma membrane and regulate their localization. SLC39A6 is known to interact with SIP and can modulate its activity. Therefore, small molecules that can inhibit SIP-SLC39A6 interactions could be a useful drug targets for SLC39A6-related diseases.

Another potential drug target for SLC39A6 is the neurotransmitter receptor, which is a protein that is expressed in many different cell types and is involved in the transmission of neural signals. SLC39A6 is known to interact with the neurotransmitter receptor, which can modulate its activity and play a role in a variety of neurological and psychiatric disorders. Small molecules that can block SLC39A6-receptor interactions could be a useful drug targets for these disorders.

In addition to these potential drug targets, SLC39A6 is also being targeted with small molecules that can modulate its structure and stability. These small molecules can include inhibitors of SLC39A6 enzymes, such as the enzyme SLC39A6-glucosidase, which is involved in the degradation of SLC39A6. In addition, small molecules that can alter SLC39A6 levels in the body, such as those that enhance its synthesis or degradation, could also be useful drug targets.

While the use of small molecules to target SLC39A6 is still in its early stages, it holds promise as a new approach to treating diseases associated with high levels of SLC39A6 expression. Further research is needed to identify reliable and effective small molecules that can be used to modulate SLC39A6 function and improve therapeutic outcomes.

Protein Name: Solute Carrier Family 39 Member 6

Functions: May act as a zinc-influx transporter

The "SLC39A6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC39A6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets